Roivant Sciences Stock Price, News & Analysis (NASDAQ:ROIV) $9.09 -0.01 (-0.11%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$8.88▼$9.1550-Day Range$8.38▼$13.1952-Week Range$5.01▼$13.24Volume7.08 million shsAverage Volume4.50 million shsMarket Capitalization$7.31 billionP/E RatioN/ADividend YieldN/APrice Target$15.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Roivant Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside68.7% Upside$15.33 Price TargetShort InterestHealthy5.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.16Based on 12 Articles This WeekInsider TradingSelling Shares$221.24 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.55) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector193rd out of 949 stocksPharmaceutical Preparations Industry78th out of 435 stocks 4.4 Analyst's Opinion Consensus RatingRoivant Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.33, Roivant Sciences has a forecasted upside of 68.7% from its current price of $9.09.Amount of Analyst CoverageRoivant Sciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.49% of the float of Roivant Sciences has been sold short.Short Interest Ratio / Days to CoverRoivant Sciences has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Roivant Sciences has recently decreased by 10.11%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRoivant Sciences does not currently pay a dividend.Dividend GrowthRoivant Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ROIV. Previous Next 1.0 News and Social Media Coverage News SentimentRoivant Sciences has a news sentiment score of -0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Roivant Sciences this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for ROIV on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Roivant Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Roivant Sciences insiders have sold 281.45% more of their company's stock than they have bought. Specifically, they have bought $58,000,008.00 in company stock and sold $221,241,743.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of Roivant Sciences is held by insiders.Percentage Held by Institutions64.76% of the stock of Roivant Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Roivant Sciences are expected to grow in the coming year, from ($1.55) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Roivant Sciences is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Roivant Sciences is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRoivant Sciences has a P/B Ratio of 4.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Roivant Sciences Stock (NASDAQ:ROIV)Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.Read More ROIV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ROIV Stock News HeadlinesNovember 29, 2023 | markets.businessinsider.comOptimistic Outlook for Roivant Sciences Despite Lupus Trial Setback: Tsao Maintains Buy RatingNovember 28, 2023 | finance.yahoo.comRoivant’s Matt Gline on raising capital and biotech’s outlook in 2024November 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 28, 2023 | finance.yahoo.comRoivant’s Matt Gline on raising capital and biotech’s outlook for 2024November 28, 2023 | markets.businessinsider.comHold Rating Maintained for Roivant Sciences Amidst Phase 2 Trial Setback and Upcoming CatalystsNovember 28, 2023 | finance.yahoo.comRoivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class PotentialNovember 27, 2023 | proactiveinvestors.comRoivant Sciences unable to determine effectiveness of lupus drug in Phase 2 studyNovember 27, 2023 | msn.comWhy Is Vivek Ramaswamy-Founded Roivant Sciences Stock Trading Lower Today?November 28, 2023 | RYSE INC. (Ad)Secure your stake in the Smart Home industry.Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.November 27, 2023 | msn.comRoivant slides on failed Phase 2 study for lupus drug candidateNovember 27, 2023 | markets.businessinsider.comRoivant: Oral Brepocitinib Fails To Meet Primary Endpoint In Phase 2 StudyNovember 27, 2023 | reuters.comRoivant Sciences' lupus drug fails to reduce symptoms in mid-stage studyNovember 27, 2023 | msn.comRoivant Sciences shares drop as lupus treatment misses trial goalNovember 27, 2023 | finance.yahoo.comRoivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus ErythematosusNovember 17, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Invitae (NVTA), Roivant Sciences (ROIV) and Exact Sciences (EXAS)November 15, 2023 | finance.yahoo.comRoivant Sciences Ltd. (NASDAQ:ROIV) Analysts Just Cut Their EPS Forecasts SubstantiallyNovember 15, 2023 | markets.businessinsider.comRoivant Sciences: Promising Future Growth Predicated on Product Expansion and Solid Financial HealthNovember 14, 2023 | finance.yahoo.comRoivant Sciences Ltd. (NASDAQ:ROIV) Q2 2023 Earnings Call TranscriptNovember 14, 2023 | markets.businessinsider.comHold Rating on Roivant Sciences Amid Revenue Shortfall and Pipeline UncertaintiesNovember 14, 2023 | finance.yahoo.comQ2 2024 Roivant Sciences Ltd Earnings CallNovember 14, 2023 | markets.businessinsider.comBuy Rating for Roivant Sciences Despite Slower Launch: An Analysis of Growth Potential and Competitive AdvantagesNovember 13, 2023 | finance.yahoo.comRoivant Sciences Ltd Reports Q2 Financial Results and Business ProgressNovember 13, 2023 | seekingalpha.comRoivant Sciences Ltd. 2023 Q2 - Results - Earnings Call PresentationNovember 13, 2023 | msn.comRoivant Sciences GAAP EPS of -$0.40 misses by $0.09, revenue of $37.1M beats by $9.98MNovember 13, 2023 | finance.yahoo.comRoivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business UpdateNovember 12, 2023 | markets.businessinsider.comRoivant Sciences earnings preview: what Wall Street is expectingNovember 10, 2023 | morningstar.comRoivant Sciences Ltd Ordinary SharesSee More Headlines Receive ROIV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Roivant Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today11/28/2023Next Earnings (Estimated)2/12/2024Fiscal Year End3/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ROIV CUSIPN/A CIK1635088 Webroivant.com Phone44-20-7400-3347FaxN/AEmployees904Year FoundedN/APrice Target and Rating Average Stock Price Target$15.33 High Stock Price Target$23.00 Low Stock Price Target$10.00 Potential Upside/Downside+68.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,009,030,000.00 Net Margins-951.77% Pretax Margin-1,177.62% Return on Equity-73.04% Return on Assets-47.29% Debt Debt-to-Equity Ratio0.29 Current Ratio5.84 Quick Ratio5.84 Sales & Book Value Annual Sales$61.28 million Price / Sales119.25 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book4.31Miscellaneous Outstanding Shares803,920,000Free Float766,941,000Market Cap$7.31 billion OptionableNot Optionable Beta1.32 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Matthew Gline (Age 39)CEO & Director Comp: $1.77MDr. Eric Venker M.D. (Age 36)Pharm.D., President & COO Comp: $1.28MDr. Mayukh Sukhatme M.D. (Age 47)President & Chief Investment Officer Comp: $1.72MMr. Richard Pulik (Age 44)Chief Financial Officer Ms. Rakhi Kumar (Age 43)Chief Accounting Officer Dr. Huafeng Xu Ph.D.Chief Technology OfficerMr. Josh ChenGeneral CounselMs. Kelly GraffHead of PeopleMs. Marianne L. Romeo (Age 55)Head of Global Transactions & Risk Management Mr. Alex GasnerExecutive Vice President of Roivant HealthMore ExecutivesKey CompetitorsExelixisNASDAQ:EXELBridgeBio PharmaNASDAQ:BBIOVaxcyteNASDAQ:PCVXVerona PharmaNASDAQ:VRNAImmunovantNASDAQ:IMVTView All CompetitorsInsiders & InstitutionsMorgan StanleyBought 6,324,915 shares on 11/16/2023Ownership: 2.502%Tudor Investment Corp Et AlSold 150,865 shares on 11/16/2023Ownership: 0.023%Public Employees Retirement System of OhioBought 31,182 shares on 11/16/2023Ownership: 0.018%GTS Securities LLCBought 24,800 shares on 11/16/2023Ownership: 0.000%Sectoral Asset Management Inc.Bought 5,020 shares on 11/15/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions ROIV Stock Analysis - Frequently Asked Questions Should I buy or sell Roivant Sciences stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roivant Sciences in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ROIV shares. View ROIV analyst ratings or view top-rated stocks. What is Roivant Sciences' stock price target for 2024? 9 Wall Street research analysts have issued 1-year price objectives for Roivant Sciences' shares. Their ROIV share price targets range from $10.00 to $23.00. On average, they anticipate the company's stock price to reach $15.33 in the next year. This suggests a possible upside of 68.7% from the stock's current price. View analysts price targets for ROIV or view top-rated stocks among Wall Street analysts. How have ROIV shares performed in 2023? Roivant Sciences' stock was trading at $7.99 on January 1st, 2023. Since then, ROIV shares have increased by 13.8% and is now trading at $9.09. View the best growth stocks for 2023 here. When is Roivant Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our ROIV earnings forecast. How were Roivant Sciences' earnings last quarter? Roivant Sciences Ltd. (NASDAQ:ROIV) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by $0.10. The firm earned $21.60 million during the quarter, compared to the consensus estimate of $24.49 million. Roivant Sciences had a negative net margin of 951.77% and a negative trailing twelve-month return on equity of 73.04%. The company's quarterly revenue was up 402.3% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.48) earnings per share. What ETFs hold Roivant Sciences' stock? ETFs with the largest weight of Roivant Sciences (NASDAQ:ROIV) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), Invesco Dorsey Wright Momentum ETF (PDP) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). Who are Roivant Sciences' major shareholders? Roivant Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include SB Investment Advisers UK Ltd. (9.46%), FMR LLC (5.04%), Morgan Stanley (2.50%), Rubric Capital Management LP (1.36%), Adage Capital Partners GP L.L.C. (0.80%) and Loomis Sayles & Co. L P (0.26%). Insiders that own company stock include Eric Venker, Financial Lp Qvt, Global Investors Lp Viking, Keith S Manchester, Matthew Gline, Pharma Technologies Ltd Dexcel, Rakhi Kumar, Richard Pulik, Sciences Ltd Roivant, Svf Investments (Uk) Ltd and Vivek Ramaswamy. View institutional ownership trends. How do I buy shares of Roivant Sciences? Shares of ROIV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ROIV) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Roivant Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.